Abstract Obstructive sleep apnea-hypopnea syndrome (OSAS) is characterized by the presence of disordered breathing events that occur during sleep, as well as symptoms such as sleepiness and snoring. OSAS is associated with a number of adverse health consequences, and a growing literature focuses on its cognitive correlates. Although research in this field is mixed, multiple studies indicate that OSAS patients show impairment in attention, memory, and executive function. Continuous positive airway pressure (CPAP) is the most effective and widely used treatment of OSAS, and supplemental medications may supplement CPAP treatment to ameliorate associated symptoms. Here, we review the literature on OSAS and cognition, including studies that have investigated the impact of CPAP and stimulant medication on cognitive performance in patients with OSAS. In general, no consistent effect of CPAP use on cognitive performance was evident. This may be due, in part, to variability in study design and sampling methodology across studies. Studies of stimulant medications generally reported positive effects on cognitive performance. We conclude with a discussion of the mechanisms that have been proposed to explain cognitive dysfunction in OSAS and directions for future research.
Introduction
Obstructive sleep apnea-hypopnea syndrome (OSAS) is a respiratory sleep disorder that is caused by a blockage or narrowing of the upper airway . In OSAS, sleep often becomes fragmented due to repeated respiratory events, which are identified as apneas when airflow is stopped for ten or more seconds, or hypopneas when airflow decreases by 30 % or more and is accompanied by a decrease in oxyhemoglobin saturation (Iber et al. 2007) . Diagnosis of OSAS is based on summary indices of respiratory events, such as the apnea-hypopnea index (AHI; mean number of apneas ? hypopneas per hour of sleep) or the respiratory disturbance index (RDI; mean number of apneas ? hypopneas ? respiratory effort-related arousals per hour of sleep) (Redline et al. 2000) . In general, an AHI of 5-15 constitutes mild OSAS, 16-30 is considered moderate, and greater than 30 is severe (Iber et al. 2007 ). The hallmark symptom of OSAS is excessive daytime sleepiness, although patients commonly experience repeated awakenings from sleep, feelings of choking or gasping, snoring, flailing or thrashing during sleep, decreased capacity for concentration, and impaired functioning in daily activities .
Deteriorations in quality of life (Finn et al. 1998 ) and affect, which can include irritability, depression, and anxiety (Sharafkhaneh et al. 2005) , are common among patients with OSAS. Fortunately, effective treatment is available for OSAS. The most consistently effective treatment is continuous positive airway pressure (CPAP), which uses a mask to deliver a calibrated level of pressure to keep the airway open, thus significantly eliminating or attenuating the occurrence of apneas and hypopneas (Atwood et al. 2005) . Alternate treatment techniques, including oral appliances, surgery, or weight loss (Grunstein et al. 2007 ), may be prescribed in circumstances where CPAP is not well tolerated or is otherwise insufficient for treating OSAS. Additionally, when CPAP treatment does not sufficiently improve daytime sleepiness, pharmacological interventions may supplement standard CPAP regimens in order to ameliorate the excessive sleepiness and fatigue (Atwood et al. 2005) .
A growing literature ties OSAS to a range of adverse health outcomes, including all-cause mortality (Yaggi et al. 2005; Marshall et al. 2008; Young et al. 2008 ) and morbidity due to stroke (Yaggi et al. 2005) , cardiovascular disease (Peker et al. 2002; Pepperell 2011) , hypertension (Carlson et al. 1994; Drager et al. 2010) , and insulin resistance (Ip et al. 2002; Babu et al. 2005) . Individuals with OSAS are also more likely to be involved in both fatal and non-fatal motor vehicle accidents (Findley et al. 1989; Masa et al. 2000; Hiestand and Phillips 2011) . Medical costs, combined with functional losses, frequently place a significant financial burden upon patients with OSAS, which in turn places economic strain upon the entire national healthcare system (Kapur 2010) .
Among the most prominent adverse consequences associated with OSAS is impairment in cognitive functioning, which is observed in many OSAS patients (Greenberg et al. 1987; Aloia et al. 2004 ). This consequence is of particular concern, given its implications for work performance, social functioning, and everyday activity. In this paper, we discuss previous research and the current understanding of cognition in OSAS; we continue this discussion with a review of empirical work that has investigated the impact of both standard and supplemental treatment interventions on cognitive performance. We then discuss several methodological issues present within the existing literature and the implications of these findings for future research.
Epidemiologic Factors
The prevalence of OSAS is estimated to be 4 % for middleaged American men and 2 % for middle-aged American women (Young et al. 1993) . Males are at a significantly higher risk for developing OSAS than females (Bixler et al. 2001) . Age is another significant risk factor for OSAS, as incidence increases steadily with age for both men and women (Ancoli-Israel et al. 1991; Young et al. 1993; Bixler et al. 1998) . Research also suggests that the burden of OSAS and its associated symptoms is greater within racial and ethnic minority groups when compared with White groups (Ancoli-Israel et al. 1995; Redline et al. 1997; O'Connor et al. 2003; Fiorentino et al. 2006) .
Prevalence estimates of OSAS vary across studies based on research design and sampling criteria (Redline et al. 2000) . The American Academy of Sleep Medicine (AASM) defines OSAS as AHI C 5 plus the presence of two or more symptoms, such as daytime sleepiness or snoring (American Academy of Sleep Medicine Task Force 1999). Many researchers hypothesize that a large proportion of the general population may suffer from an elevated AHI, but does not experience any associated symptoms (Young et al. 1997) . For example, in a representative sample of US men, the prevalence of OSAS (defined by AHI [ 10 and the presence of daytime symptoms) was 3.3 %, while the prevalence of any AHI [ 5 was 17 %, indicating that many individuals endure respiratory events but may not experience, or report, the symptoms of OSAS (Bixler et al. 1998) . Similarly, Young et al. (1993) reported that 9 % of women and 24 % of men had an AHI C 5, but were asymptomatic for OSAS. Thus, current prevalence estimates of OSAS do not capture everyone suffering from sleep-disordered breathing. In one representative sample, one in four US adults was identified as being at high risk for OSAS (Hiestand et al. 2006) .
Cognitive Impairment Associated with OSAS
Although the extent of cognitive dysfunction in OSAS is not fully understood (Quan et al. 2006; Sforza et al. 2010; Quan et al. 2011) , several prior reviews of the literature suggested that OSAS patients exhibit significant impairment on neuropsychological tests (Décary et al. 2000; Sateia 2003; Aloia et al. 2004; El-Ad and Lavie 2005) . Authors who have previously reviewed the evidence on OSAS and cognition have categorized cognition into four discrete (although not mutually exclusive) domains: intellectual function, memory, attention, and executive function (Décary et al. 2000; Sateia 2003 ). We follow the same categorization scheme in our review of the current literature.
Relatively little research has specifically examined the influence of OSAS on intellectual function. Deficits in measures of global intellectual function have been reported by individual studies (Findley et al. 1986; Greenberg et al. 1987; Bédard et al. 1991) . However, a meta-analysis of twenty-five studies reported no significant impairment in intellectual function in OSAS patients compared with control subjects and normative data (Beebe et al. 2003) . One study reported that OSAS patients with intellectual function scores in the 90th percentile maintained normative attentional capacity, which suggests that high intellectual function may protect against the deterioration of some other cognitive abilities in OSAS (Alchanatis et al. 2005) .
More commonly, researchers have investigated whether OSAS has an impact within the domain of memory. Although several individual studies have suggested that OSAS patients experience impairments in both short-term and long-term memory (Bédard et al. 1991; Naëgelé et al. 1995; Salorio et al. 2002; Bawden et al. 2011 ), these findings were not supported by a meta-analysis (Beebe et al. 2003) . More recent work suggests that OSAS patients perform significantly worse on tests of verbal memory, but not visual memory, when compared with controls (Kloepfer et al. 2009; Twigg et al. 2010) . Taken together, this literature suggests that individuals with OSAS may exhibit impairments in some aspects of memory.
The observation that OSAS patients are at increased risk for motor vehicle accidents (Terán-Santos et al. 1999; Masa et al. 2000) has spurred investigation of cognitive capacities in OSAS, especially relative to the processes of attention. Driving simulation instruments are designed to mimic real-world driving conditions and therefore measure the reaction time and sustained attention of subjects (Pichel et al. 2006) . Individuals with OSAS have consistently exhibited worse performance in these simulations compared with controls (Findley et al. 1989; George et al. 1996; Juniper et al. 2000; Tippin et al. 2009) . Differences between OSAS patients and controls have been shown on more traditional neuropsychological tests of attention (Mazza et al. 2005; Bawden et al. 2011; Shpirer et al. 2011) , and these findings were corroborated by the results of a meta-analysis (Beebe et al. 2003) .
A fourth cognitive domain, executive function, refers to the higher order cognitive processes including problemsolving, judgment, inhibition and set switching, and cognitive flexibility (Alvarez and Emory 2006) . Several studies have suggested that executive function may be significantly impacted by OSAS (Lis et al. 2008; Bawden et al. 2011) . One systematic review posited that executive function may be the cognitive domain most impaired in OSAS (Saunamäki and Jehkonen 2007) . Specifically, patients show impairment on tests that require set shifting, mental flexibility, and planning (Saunamäki et al. 2009 ). Other authors have reported disturbances in some, but not all, measures of executive function in OSAS patients (Salorio et al. 2002) . Despite mixed results, the bulk of this literature suggests that executive function is impaired to some degree in patients with OSAS.
Effect of CPAP Treatment on Cognition
A question of great clinical and public health relevance is whether, and to what extent, the cognitive deficits exhibited by individuals with OSAS may be improved by standard treatment techniques. In the following section, we review empirical studies that have investigated the effect of CPAP treatment on neuropsychological performance in OSAS patients. Studies in this area vary by sample characteristics, methodology, and design and include traditional randomized controlled trials (RCTs) as well as case-control designs and within-subject studies. There is a dearth of RCTs in this area of research. The randomization of patients to a placebo condition has raised ethical concerns (Karlawish and Pack 2001) as CPAP is well established as the gold-standard treatment for OSAS. Nevertheless, since most OSAS patients have lived with their OSAS for many years before being diagnosed, randomization to up to 3 weeks of placebo CPAP is often used as it is only with comparisons to placebo that the true effect of CPAP can be established. Nevertheless, many investigators have utilized a randomized crossover design or have simply employed a non-randomized study design. Although previous research has investigated the cognitive effects of CPAP treatment in RCTs (Sánchez et al. 2009 ), we chose to consider the wide range of study designs in our review.
The sample characteristics, designs, and main findings from the RCTs of CPAP treatment on cognition are presented in Table 1 . Six of these trials reported no significant difference in cognitive performance between the CPAP and control groups following treatment (Engleman et al. 1998; Lojander et al. 1999; Monasterio et al. 2001; Ancoli-Israel et al. 2008; Gagnadoux et al. 2009; Vennelle et al. 2010; Ryan et al. 2011 ). On the other hand, seven other trials reported significant differences between these groups following CPAP treatment in the domains of attention (Engleman et al. 1994 (Engleman et al. , 1999 Barbé et al. 2001; Lim et al. 2007 ) and executive function (Engleman et al. 1994 (Engleman et al. , 1997 (Engleman et al. , 1999 Barnes et al. 2002) . Other studies reported improved performance in patients from pre-CPAP to post-CPAP in the specific domains of executive function (Henke et al. 2001; Gagnadoux et al. 2009 ) and attention (Henke et al. 2001; Lim et al. 2007; Ryan et al. 2011) , as well as on a composite neuropsychological battery (Bardwell et al. 2001; Ancoli-Israel et al. 2008 ).
Significant improvement in cognitive performance following CPAP treatment was reported in studies that utilized a within-subjects design. These studies reported improvements in memory (Bédard et al. 1993; Aloia et al. 2003; Joseph et al. 2009; Zimmerman et al. 2006) , attention (Bédard et al. 1993; Aloia et al. 2003) , and executive function (Aloia et al. 2003; Gale and Hopkins 2004) after 3 months (Aloia et al. 2003; Zimmerman et al. 2006 ) and 6 months (Bédard et al. 1993; Gale and Hopkins 2004; Joseph et al. 2009 ) of follow-up. Studies that utilized a case-control design also reported improvements in OSAS patients treated with CPAP compared with age-matched healthy control subjects. Specifically, cognition improved in areas of memory (Tonon et al. 2007 ; Canessa et al. (Muñoz et al. 2000) , motor speed, and executive function (Naëgelé et al. 1998; FeriniStrambi et al. 2003) . Three studies investigated cognitive performance after CPAP in individuals with diagnosed neurological conditions, namely patients with mild probable Alzheimer's disease (AD) Cooke et al. 2009 ) and patients recovering from recent stroke (Hsu et al. 2006; Ryan et al. 2011 ). An RCT of CPAP treatment in AD reported that, following 3 weeks of CPAP treatment, general cognitive performance improved within a sample of OSAS patients with AD although, likely due to insufficient power, no differences in improvement between the CPAP condition and the control condition were observed (AncoliIsrael et al. 2008) . Follow-up analyses on a subset of this sample suggested that adherent CPAP use might slow cognitive decline, especially in the domain of executive function and processing speed, in AD patients with OSAS (Cooke et al. 2009 ). In two RCTs of recent stroke patients, no significant differences in cognitive performance were observed when the CPAP condition was compared with the control (in this case standard rehabilitation) condition (Hsu et al. 2006; Ryan et al. 2011) , although digit and visual span backward did improve within the CPAP group following 1 month of treatment (Ryan et al. 2011 ). Taken together, these studies provide some preliminary evidence that AD or stroke patients with sleep-disordered breathing may experience some cognitive benefit from CPAP treatment. Because cognitive impairment related to OSAS is not well understood in these populations, additional RCTs are needed in order to better understand the impact of CPAP on cognition in populations with identified neurologic disease.
One striking feature of studies of CPAP and cognition is the between-study variability in duration of exposure to CPAP treatment. For example, some studies investigated cognitive change after 1 week of CPAP use (Bardwell et al. 2001) , while others followed subjects for up to 12 months (Muñoz et al. 2000) . Some have argued that no doseresponse relationship exists between the length of time on CPAP treatment and the level of cognitive improvement (Valencia-Flores et al. 1996) . This argument is supported by a finding that CPAP use was associated with improved attention, spatial ability, and motor speed in OSAS patients, and these results were the same after 15 days of follow-up as the results after 4 months (Ferini-Strambi et al. 2003) . Similarly, another study reported that, although cognition improved after 3 weeks, no differences in performance were observed between 3 and 6 weeks of CPAP treatment ). Significant improvements in cognition were observed after just 1 (Bardwell et al. 2001 ) and 2 weeks (Lim et al. 2007 ) of CPAP treatment. In an exception to this pattern, one study reported that sustained attention improved in patients compared to controls after 3 months of CPAP treatment and continued to improve following 12 months of treatment (Muñoz et al. 2000) .
Another noticeable source of heterogeneity in this research is differential inclusion and exclusion criteria. Although some studies utilized the AASM guidelines for determining study eligibility, (Engleman et al. 1993 (Engleman et al. , 1997 (Engleman et al. , 1998 (Engleman et al. , 1999 (Engleman et al. , 2002 Ferini-Strambi et al. 2003; Zimmerman et al. 2006; Tonon et al. 2007; Gagnadoux et al. 2009; Vennelle et al. 2010) , others included subjects based solely on the number of respiratory events that occurred during sleep, regardless of symptom presence (Bardwell et al. 2001; Barnes et al. 2002; Lim et al. 2007; Ryan et al. 2011) . The AHI cut-off used to select subjects also varied across studies; some included participants with an AHI C 5 or AHI C 10 (Muñoz et al. 2000; Lim et al. 2007; Cooke et al. 2009; Joseph et al. 2009; Saunamäki et al. 2010) , while others included subjects with AHI C 20 (Borak et al. 1996; Barbé et al. 2001; Ferini-Strambi et al. 2003; Canessa et al. 2011) . Few authors chose to utilize the alternative RDI measurement (Aloia et al. 2003; Lau et al. 2010) in the evaluation of respiratory events. Because the RDI can be calculated using several methods, this measurement may not always reliably identify the severity of OSAS (Redline et al. 2000) . Few studies included an inclusion/exclusion criterion to establish the baseline cognitive status of samples, which is problematic because baseline cognitive status may play a substantial role in the response of an individual to CPAP treatment. Additionally, if a sample is not well characterized with respect to baseline cognitive performance, then it becomes difficult for researchers to generalize study results to populations with known levels of cognitive function.
CPAP adherence is another methodological issue present within this literature, as it is well established that many OSAS patients do not correctly follow their prescribed treatment regimen (Yetkin et al. 2008) . Unfortunately, few studies that used CPAP included a mechanism for tracking adherence in participants, and without this form of monitoring, it becomes impossible to control for the confounding effects of CPAP non-adherence. Studies that contained a tracking mechanism reported that adherence to CPAP treatment was associated with cognitive improvement after 3 months (Aloia et al. 2003; Zimmerman et al. 2006) . These findings suggest that adherence is an important factor in predicting the strength of the association between CPAP treatment and cognitive change (Wild et al. 2004) .
A final research consideration in this field is that many neuropsychological tests are susceptible to practice effects. As others have suggested (Aloia et al. 2003; Ferini-Strambi et al. 2003; Zimmerman et al. 2006 ) alternate forms of the neuropsychological tests should be utilized where possible to minimize the potential for practice effects. However, in the presence of short test-retest intervals, even in withinsubjects studies where alternate forms are utilized, practice effects may not be completely diminished.
When this body of work was considered together, no clear trends emerged. Rather, the results of these studies were mixed, and the findings differed greatly in terms of the timing and magnitude of cognitive change that followed CPAP treatment. In fact, several studies have reported that CPAP treatment has no effect on cognitive performance (Engleman et al. 1998; Monasterio et al. 2001; Barbé et al. 2001; Hsu et al. 2006; Vennelle et al. 2010) . Most other research reported that CPAP had some (at least mild) positive implication for cognitive performance in OSAS patients, especially in the areas of sustained attention (Muñoz et al. 2000; Lim et al. 2007; Lau et al. 2010) , psychomotor speed (Ferini-Strambi et al. 2003; Lau et al. 2010) , and short-term memory (Tonon et al. 2007 ). Furthermore, authors suggest that compliant CPAP use is an important factor in determining the magnitude of cognitive improvement (Aloia et al. 2003; Zimmerman et al. 2006 ).
Effect of Pharmacological Intervention on Cognition
Attention is often affected by daytime sleepiness. Because the studies that have investigated cognition following CPAP treatment have produced mixed results, researchers have investigated the possible cognitive benefits of supplemental pharmacological treatment for daytime sleepiness in OSAS. The non-amphetamine stimulant medications modafinil and armodafinil are approved by the United States Food and Drug Administration to treat daytime sleepiness in OSAS patients (Atwood et al. 2005) . In a pilot study of modafinil, long-term memory was improved after 2 weeks of treatment (Arnulf et al. 1997) . Subsequent RCTs reported that OSAS patients treated with modafinil performed significantly better compared with placebo groups on tests of reaction time (Dinges and Weaver 2003) and sustained attention (Dinges and Weaver 2003; Bittencourt et al. 2008 ) after 3 weeks (Bittencourt et al. 2008 ) and 4 weeks (Dinges and Weaver 2003) of treatment. In RCTs of modafinil effectiveness following acute discontinuation of CPAP treatment, reaction time and sustained attention were better in the treatment group than in the control group in some (Williams et al. 2010 ), but not all (Williams et al. 2008) samples. Differences in episodic long-term memory have been demonstrated within OSAS patient groups treated with CPAP and armodafinil (Hirshkowitz et al. 2007; Roth et al. 2008) and in groups treated with only armodafinil (Roth et al. 2006 ) compared with control conditions. In general, these findings indicate that stimulant medications might improve memory and attention among adults with OSAS.
Mechanisms Underlying Cognitive Impairment in OSAS
Several mechanisms linking OSAS to cognitive dysfunction have been proposed, and multiple processes likely contribute to this impairment ( Fig. 1) (Valencia-Flores et al. 1996; Décary et al. 2000) . In fact, some researchers have argued that the mechanisms underlying the observed cognitive impairment can be distinguished based on the type of cognitive deficit present in OSAS patients (Bédard et al. 1991; Naismith et al. 2004) . Daytime somnolence is one proposed cause of cognitive dysfunction in OSAS, particularly in the domains of attention and executive function (Naismith et al. 2004) . In support of this argument, one study reported that slower reaction time was correlated with increased subjective sleepiness in a sample of OSAS patients (Lis et al. 2008) . Work in older adults has suggested that the presence of excessive daytime sleepiness increases the risk for impairment in multiple domains of cognition (Cohen-Zion et al. 2001; Ohayon and Vecchierini 2002) . In the study on the effect of CPAP treatment on cognition in AD, the CPAP treatment also improved daytime sleepiness (Chong et al. 2006) , which might have accounted for some of the improvement in overall cognitive function.
A second proposed mechanism for cognitive dysfunction in OSAS is intermittent hypoxemia (Findley et al. 1986; Greenberg et al. 1987; Quan et al. 2011) . It has been observed that hypoxemic OSAS patients have worse performance on cognitive tests when compared with nonhypoxemic OSAS patients (Findley et al. 1986 ). Elevated measures of hypoxemia in OSAS patients have been associated with declines in motor and processing speed (Quan et al. 2006) , spatial abilities, processing speed, and mental flexibility (Naismith et al. 2004) , and attention (Shpirer et al. 2011) in some, but not all (Cohen-Zion et al. 2004; Lis et al. 2008 ) studies. Increased levels of hypoxemia have also been associated with risk of developing dementia or mild cognitive impairment (Yaffe et al. 2011 ). This mechanism has been further supported in animal models, where hypoxemia was associated with adverse cognitive outcomes (Row 2007; McCoy et al. 2010) . Some researchers argue that intermittent hypoxemia, together with sleep fragmentation, leads to prefrontal cortical degeneration, which could explain the impairment in executive function observed in patients with OSAS (Beebe and Goza 2002) .
In addition, others have argued that sleep fragmentation is an important mechanistic factor in the development of cognitive impairment in OSAS (Engleman et al. 1994; Ayalon et al. 2009; Verstraeten and Cluydts 2004) . For example, the number of arousals from sleep is a strong predictor of memory impairment in OSAS (Daurat et al. 2008) . Work in older adults with OSAS has concluded that cognitive decline is related to the number of respiratory disturbances that occurred during sleep-independent of hypoxemia (Cohen-Zion et al. 2004 ). In the study on the effect of CPAP treatment on cognition in AD, the CPAP treatment also improved sleep architecture with deeper sleep which might have accounted for some of the improvement in overall cognitive function (Cooke et al. 2006) . In animal studies, sleep fragmentation has been associated with poorer cognitive performance and reduction in neurogenesis (Sportiche et al. 2010) .
Another potential mechanism that may contribute to cognitive impairment in OSAS is disruption in circadian rhythms. Researchers have reported an association between disturbed circadian rhythms (as measured by actigraphy) and severity of cognitive impairment in a sample of nursing home patients (Ancoli-Israel et al. 1997) . A more recent longitudinal study found that older women who had lower amplitude and robustness of activity rhythms, also measured using actigraphy, had significantly greater odds of developing dementia or mild cognitive impairment than older women with the higher amplitude and robustness of activity rhythms (Tranah et al. 2011) . Individuals who repeatedly experience jet lag have been shown to have altered cortisol levels and impaired memory function when compared with control subjects (Cho et al. 2000) . Further, experimental animal research suggests that disruptions of circadian rhythms produce decreases in mental flexibility (Karatsoreos et al. 2011 ) and learning and memory (Craig and McDonald 2008; Gibson et al. 2010) . Research has also shown that circadian rhythms, as measured through cytokine and hormone levels (Entzian et al. 1996) and heart rate activity (Noda et al. 1993) , are altered in OSAS patient groups. Although we are unaware of research directly examining circadian rhythms and cognition in samples of OSAS patients, circadian disruptions may contribute to cognitive impairment in this group.
Because the prevalence of OSAS is higher among patients with dementia than among the general population (Ancoli-Israel et al. 1991; Hoch et al. 1986; Sharafkhaneh et al. 2005; Rongve et al. 2010; Kim et al. 2011) , some researchers have hypothesized that OSAS may contribute to the development of dementia. Further, OSAS and dementia share common risk factors, including the presence of apolipoprotein e4 allele (APOE4) (Bliwise 2001) . This well-known genetic risk factor for Alzheimer's disease and cognitive impairment (Strittmatter et al. 1993; Caselli et al. 2004; Crean et al. 2011 ) has also been associated with increased risk for OSAS (Kadotani et al. 2001; Gottlieb et al. 2004) . Some studies have even reported an inverse relationship between AHI severity and global cognitive status (Spira et al. 2008 ) as well as memory performance (O'Hara et al. 2005; Cosentino et al. 2008) in APOE4 carriers compared with non-carriers. This work suggests that APOE4 status may modify the risk of cognitive impairment in OSAS patients.
A host of other variables may also influence the development of cognitive impairment in OSAS, as many of the most prominent risk factors for OSAS are also risk factors for cognitive impairment. For example, the risk for OSAS increases with age (Young et al. 1993) , as does the risk for cognitive impairment. In one study, younger adults with OSAS performed better on cognitive tests than older adults with OSAS. Although performance did not differ between the younger patient group and age-matched controls, the older patient group showed significant cognitive impairment compared with age-matched controls (Alchanatis et al. 2008) . In addition to being a risk factor for both cognitive impairment and OSAS, increased age represents vulnerability to several other medical conditions and disturbances in sleep duration and architecture (Van Someren 2000; Ancoli-Israel and Cooke 2005) . Another primary risk factor for OSAS, obesity, has been associated with cognitive decline (Jeong et al. 2005 ) and the development of dementia (Whitmer et al. 2007 (Whitmer et al. , 2008 . Cardiovascular illnesses, such as hypertension and stroke, represent other potential mediators in the association between cognitive dysfunction and OSAS, given that studies have identified cardiovascular disease as a risk factor for cognitive impairment (Kilander et al. 1998 ) and OSAS (Peker et al. 2002; Drager et al. 2010; Pepperell 2011 ).
Summary and Conclusion
OSAS is a medical condition of serious clinical and health significance because of its high prevalence, potential for under-diagnosis, and adverse health consequences. Cognitive deficits have long been observed in OSAS patients, and although findings in this domain remain inconsistent, evidence exists for deficits in intellectual function, memory, attention, and executive function in OSAS.
Due to the mixed results of treatment studies, which may be due to variability in inclusion and exclusion criteria, study design, and duration of treatment, it is not possible to make definitive conclusions regarding the impact of CPAP treatment on cognition in OSAS. Although CPAP is a well-established, effective treatment for OSAS, it does not definitively reduce the host of cognitive deficits observed among OSAS patients. In addition to studies of CPAP, we reviewed studies that evaluated the effectiveness of non-amphetamine stimulant medications at improving cognition in OSAS patients. The results from these trials indicate that cognitive performance improved in OSAS patients following treatment with modafinil or armodafinil. Further trials are needed to determine the extent to which stimulant medications, alone or in combination with CPAP, may enhance the daily functioning of patients with OSAS.
Future studies are needed to better understand the mechanisms underlying the causes of cognitive decline in OSAS. This understanding will be achieved through work in neuroimaging and animal models. Large-scale longitudinal RCT studies are needed to improve our understanding of how cognitive impairment in OSAS patients develops over time. Additional RCTs are needed to determine whether or not CPAP treatment causes cognitive improvement in OSAS patients. Finally, future studies that take a standardized approach to neuropsychological evaluation and subject selection criteria using the diagnostic guidelines set forth by the AASM are needed to aid in comparison with results across studies.
